This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Medical Products Stock Feb 6 Earnings Roster: BDX, CAH & More
by Zacks Equity Research
Despite the ongoing US-China trade war, increased focus on innovation is likely to have driven performance of medical products players' quarterly performance.
Thermo Fisher (TMO) Q4 Earnings Top, Organic Growth Solid
by Zacks Equity Research
We are upbeat that two of Thermo Fisher's (TMO) four business segments deliver strong year-over-year revenue growth in Q4.
Thermo Fisher Scientific (TMO) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Thermo Fisher (TMO) delivered earnings and revenue surprises of 0.28% and 0.67%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Why Thermo Fisher Scientific (TMO) Might Surprise This Earnings Season
by Zacks Equity Research
Thermo Fisher Scientific (TMO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Medical Products' Jan 30 Earnings Roster: TMO, EW & More
by Zacks Equity Research
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.
What's in Store for Thermo Fisher (TMO) in Q4 Earnings?
by Zacks Equity Research
Strength in segments is expected to get reflected in Thermo Fisher's (TMO) fourth-quarter and 2019 top-line numbers.
Thermo Fisher Scientific (TMO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Thermo Fisher (TMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Thermo Fisher Hits New 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Thermo Fisher (TMO) is optimistic about maintaining its growth momentum on several recent developments.
Why Thermo Fisher (TMO) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Is Thermo Fisher Scientific (TMO) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (TMO) Outperforming Other Medical Stocks This Year?
Thermo Fisher Rides on New Product Suite, Currency Woes Stay
by Zacks Equity Research
Thermo Fisher Scientific (TMO) recently unveils a product suite comprising the TSQ Altis, Quantis MD mass spectrometers and Vanquish MD HPLC.
Here's Why You Should Retain Pacific Biosciences Stock Now
by Zacks Equity Research
Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, stiff competition remains a woe.
Here's Why You Should Hold on to Thermo Fisher Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Thermo Fisher (TMO) on its stellar segmental performance.
The Zacks Analyst Blog Highlights: QUALCOMM, NVIDIA, Charter, Microsoft and Thermo Fisher Scientific
by Zacks Equity Research
The Zacks Analyst Blog Highlights: QUALCOMM, NVIDIA, Charter, Microsoft and Thermo Fisher Scientific
5 Corporate Giants That Popped in 2019 and Have Upside Left
by Nalak Das
A stable U.S. economy, a partial trade deal with China, possible solution of Brexit and easy monetary policy of the Fed are likely to sustain Wall Street's rally in 2020.
Thermo Fisher (TMO) at a 52-Week High: What's Driving It?
by Zacks Equity Research
Thermo Fisher (TMO) gains from solid overseas expansion and acquisitions.
Patterson Companies (PDCO) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Patterson Companies' (PDCO) Q2 results benefit from higher revenues, gross margin expansion and solid show by Dental segment.
What's in the Cards for Cantel Medical (CMD) in Q1 Earnings?
by Zacks Equity Research
Better-than-expected performance at both Medical and Dental segments is likely to have driven Cantel Medical (CMD) in Q1 earnings.
Here's Why You Should Hold on to HealthEquity (HQY) for Now
by Zacks Equity Research
Buoyed by a solid fiscal third quarter, HealthEquity (HQY) raises its fiscal 2020 view.
HealthEquity (HQY) Earnings & Revenues Beat Estimates in Q3
by Zacks Equity Research
Buoyed by a solid fiscal third quarter, HealthEquity (HQY) raises its fiscal 2020 view.
Thermo Fisher Rides on New Product Suite and Global Growth
by Urmimala Biswas
A series of product launches with better precision medicine initiatives aids Thermo Fisher's (TMO) performance.
The Zacks Analyst Blog Highlights: Procter & Gamble, Thermo Fisher, PayPal, NextEra Energy and Enterprise Products
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Procter & Gamble, Thermo Fisher, PayPal, NextEra Energy and Enterprise Products
Cooper Companies (COO) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Better-than-expected performance at CVI and CSI, and higher revenues are likely to have aided Cooper Companies (COO) in Q4 earnings.
Top Analyst Reports for Procter & Gamble, Thermo Fisher & PayPal
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble (PG), Thermo Fisher (TMO) and PayPal (PYPL).
Veeva Systems (VEEV) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Veeva (VEEV) gains from solid segmental contributions in fiscal third quarter, raises fiscal 2020 view.